Perbak Capital Partners LLP Sells 19,220 Shares of QIAGEN N.V. $QGEN

Key Points

• Perbak Capital Partners LLP has reduced its position in QIAGEN N.V. by 56.4%, now holding 14,857 shares valued at approximately $597,000 after selling 19,220 shares in the first quarter.
• Institutional interest in QIAGEN is strong, with 70% of the stock owned by hedge funds and institutional investors, including Graham Capital Management which increased its stake by 92.7% during the same period.
• Analysts have mixed views on QIAGEN, with price targets raised by Bank of America and UBS Group, but overall ratings leaning towards a "Hold" from most analysts.

Perbak Capital Partners LLP trimmed its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 56.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,857 shares of the company's stock after selling 19,220 shares during the period. Perbak Capital Partners LLP's holdings in QIAGEN were worth $597,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in QIAGEN by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock valued at $972,191,000 after buying an additional 2,656,136 shares during the period. Deutsche Bank AG boosted its holdings in shares of QIAGEN by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of QIAGEN by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock worth $179,501,000 after purchasing an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of QIAGEN by 4.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after purchasing an additional 109,481 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of QIAGEN during the fourth quarter worth about $95,746,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

QIAGEN Stock Up 0.6%

QGEN stock traded up $0.30 on Thursday, reaching $47.00. 835,598 shares of the company traded hands, compared to its average volume of 1,408,441. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The company has a market cap of $10.45 billion, a P/E ratio of 27.77, a price-to-earnings-growth ratio of 2.47 and a beta of 0.64. The firm has a fifty day simple moving average of $48.66 and a 200-day simple moving average of $44.30.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same quarter last year, the company earned $0.55 EPS. The firm's revenue for the quarter was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on QGEN shares. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Cowen reissued a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Bank of America boosted their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. UBS Group boosted their price objective on shares of QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Barclays initiated coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target for the company. Three research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, QIAGEN currently has an average rating of "Hold" and a consensus price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.